Metabolic dysfunction-associated steatotic liver disease (MASLD)-related HCC accumulates exhausted CD8+PD-1+ T cells in the TME, and preclinical studies showed that anti-PD-1 treatment led to tumor progression rather than regression in such cases[142]. This evidence concerns the gene CD8A and hepatocellular carcinoma.